Regenicin Stock Today
| RGIN Stock | USD 0.0001 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 44
|
Regenicin is selling at 1.0E-4 as of the 25th of November 2024; that is No Change since the beginning of the trading day. The stock's open price was 1.0E-4. Regenicin has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Regenicin are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 153.48 M outstanding shares. More on Regenicin
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Regenicin Pink Sheet Highlights
| Chairman, CEO and Pres | Randall McCoy |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Regenicin [RGIN] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 214.88 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regenicin's market, we take the total number of its shares issued and multiply it by Regenicin's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Regenicin conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 153.48 M outstanding shares.
Regenicin currently holds about 2.24 K in cash with (27.29 K) of positive cash flow from operations.
Check Regenicin Probability Of Bankruptcy
Ownership AllocationRegenicin owns a total of 153.48 Million outstanding shares. Regenicin holds 18.15 pct. of its outstanding shares held by insiders and 0.018 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Regenicin Ownership Details
Regenicin Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Regenicin without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
| All Next | Launch Module |
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.